Inclusion Criteria for Cohort 1:  Women will be ≥45 years of age and meet at least one of the following criteria:  Abnormal uterine bleeding Postmenopausal bleeding  Exclusion Criteria for Cohort 1:  Prior hysterectomy Current known pregnancy diagnosis Any prior pelvic or vaginal radiotherapy Any prior cancer (except basal cell skin cancer) within the past 5 years Chemotherapy within the past 5 years Current biopsy-proven cervical, vaginal, or vulvar cancer or lower genital tract dysplasia Current biopsy-proven endometrial cancer or endometrial hyperplasia - - Current biopsy-proven benign endometrial polyp Endometrial biopsy/sampling within the preceding 1 month showing benign endometrium  Inclusion Criteria for Cohort 2:  Women will be ≥18 years of age and meet at least one of the following criteria:  Presence of biopsy-proven EC (any histology, including uterine carcinosarcoma) and surgical intervention planned. Surgical intervention can include any of the following: hysterectomy, D&C, hysteroscopic resection Biopsy showing AEH or EIN with surgical intervention planned. Surgical intervention can include any of the following: hysterectomy, D&C, hysteroscopic resection, etc)  Exclusion Criteria for Cohort 2:  Undergoing surgical procedure for recurrent or metastatic EC Receipt of preoperative neoadjuvant chemotherapy or radiotherapy for current EC diagnosis Prior hysterectomy Current known pregnancy diagnosis Prior or current biopsy-proven cervical cancer Presence of concomitant biopsy-proven cervical dysplasia Any prior pelvic or vaginal radiotherapy Any prior cancer (except basal cell skin cancer) within the past 5 years Chemotherapy within the past 5 years Prior intervention or surgery with intent to completely remove the target pathology  Inclusion Criteria for Cohort 3:  Women will be ≥18 years of age, have a cervix and meet at least one of the following criteria:  History of current abnormal cervical/endocervical Pap test for which the patient is presenting for colposcopy Cervical mass identified on physical exam and patient referred for cervical biopsy, even if colposcopy not recommended or indicated Planned clinically indicated surgical excisional biopsy or removal of the cervix (cold knife cone, LEEP, hysterectomy) for abnormal Pap test, cervical dysplasia, cervical mass, or biopsy-proven invasive cervical cancer (adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, or less common primary cervical carcinomas all eligible)  Exclusion Criteria for Cohort 3:  History of pelvic or vaginal radiotherapy Prior total hysterectomy (cervix removed) for any indication Current known pregnancy diagnosis Cervical mass biopsy-proven to be EC or a cancer metastatic from a non-cervical origin Any prior cancer (except basal cell skin cancer) within the past 5 years Chemotherapy within the past 5 years Patients presenting for colposcopy as part of lower genital tract dysplasia or cancer surveillance after prior curative intent treatment and no current Pap abnormality or cervical mass Prior intervention or surgery with intent to completely remove the target pathology  Inclusion Criteria for Cohort 4:  Women will be ≥45 years of age and should meet at least one of the following criteria:  Undergoing hysterectomy with biopsy-proven or clinically presumed (based on imaging and/or clinical symptoms) benign gynecologic or uterine pathology of fibroids, endometriosis, adenomyosis, or benign endometrial polyps. Undergoing any gynecologic surgery in which a benign pathologic tissue diagnosis of fibroids, endometriosis, adenomyosis, or benign endometrial polyp is anticipated to be confirmed.  Exclusion Criteria for Cohort 4:  Endometrial biopsy or office hysteroscopy within 2 weeks preceding the planned gynecologic surgery procedure for fibroids, endometriosis, benign endometrial polyps, or adenomyosis Any surgery within the past 3 months Prior hysterectomy Current known pregnancy diagnosis Prior or current biopsy-proven gynecologic cancer Current biopsy-proven AEH/EIN, cervical, vaginal, or vulvar dysplasia Prior pelvic or vaginal radiotherapy Any prior cancer (except basal cell skin cancer) within the past 5 years Chemotherapy within the past 5 years Undergoing hysterectomy for prolapse without a coexisting known or presumed benign uterine pathologic diagnosis of fibroids, endometriosis, benign endometrial polyps, or adenomyosis Prior intervention or surgery with intent to completely remove the target pathology  Inclusion Criteria for Cohort 5:  Women will be ≥45 years of age and should meet the following criteria:  Presenting for well-woman exam, ± Pap test No change in medical conditions, new diagnoses, or new medications within the past 6 months;  Exclusion Criteria for Cohort 5:  Pap test or cervical biopsy within the past 1 month Endometrial biopsy or office hysteroscopy within the past 1 month Any surgery within the past 3 months Prior hysterectomy Current known pregnancy diagnosis Prior or current biopsy-proven gynecologic cancer Current biopsy-proven AEH/EIN, cervical, vaginal, or vulvar dysplasia Prior pelvic or vaginal radiotherapy Any prior cancer (except basal cell skin cancer) within the past 5 years Chemotherapy within the past 5 years Criteria met for inclusion in any of the other study cohorts